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Abstract
Background: Tartary buckwheat bran is an important natural source of quercetin and isoquercetin. Quercetin and
isoquercetin are both powerful a-glucosidase inhibitors. Although the IC50 of isoquercetin as a-glucosidase
inhibitor was much higher than that of quercetin, the bioavailability of isoquercetin was higher than that of
quercetin. Hence, we are interested in the antidiabetic effect of isoquercetin in diabetic KK -A
y mice.
Methods: The hypoglycemic effect of isoquercetin in a type 2 diabetic animal model (KK-A
y mice) was studied.
Isoquercetin was administrated at doses of 50, 100 and 200 mg/kg for 35 days.
Results: It was found that fasting blood glucose concentration was decreased with the 200 mg/kg group (p <
0.01) the most efficient compared with the diabetic control group. In addition, there was significant decrease in
plasma C-peptide, triglyceride, total cholesterol and blood urea nitrogen levels after 35 days. Meanwhile, glucose
tolerance was improved, and the immunoreactive of pancreatic islets b-cells was promoted.
Conclusions: These results suggest that isoquercetin had a regulative role in blood glucose level and lipids, and
improved the function of pancreatic islets. Isoquercetin may be useful in the treatment of type 2 diabetes mellitus.
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Introduction
Diabetes, especially type 2 diabetes, is rapidly becoming
an enormous health burden by decreasing quality of life
and causing death and disability in the whole world, all
at a huge economic cost. Diabetes is, in part, related to
the amount of carbohydrates in the diet. Acting as a key
enzyme for carbohydrate digestion, intestinal a-glucosi-
dase is one of the glucosidases located at the epithelium
of the small intestine. a-Glucosidase has been recog-
nized as a therapeutic target for modulation of post-
prandial hyperglycemia, which is the earliest metabolic
abnormality to occur in type 2 diabetes mellitus [1,2].
The inhibition on intestinal a-glucosidases would delay
the digestion and absorption of carbohydrates and con-
sequently suppress the postprandial hyperglycemia [3,4].
Tartary buckwheat bran is an important natural source
of quercetin and isoquercetin. Quercetin and isoquercetin
are both powerful a-glucosidase inhibitors [5]. The IC50
of quercetin was about five times lower than that of acar-
bose which has been used as effective a-glucosidase inhi-
bitors to delay glucose absorption in clinical [6]. Quercetin
significantly decreased the plasma glucose level and
improved the biochemical profiles in the streptozocin-
induced diabetic rats in a dose-dependent manner [7].
Diabetic KK-A
y mice have been frequently used as an
animal model for noninsulin-dependent diabetes [8,9].
The symptoms of this animal model are similar to dia-
betic patients and the mice exhibit metabolism abnorm-
alities such as an absolute or relative lack of insulin,
hyperglycemia and glucose intolerance, higher lipid and
so on. We are interested in the antidiabetic effect of iso-
quercetin in KK -A
y mice. Although the IC50 of isoquer-
cetin as a-glucosidase inhibitor was much higher than
that of quercetin [5], the bioavailability of isoquercetin
was higher than that of quercetin [10]. Morand et al.
[11] also demonstrated that isoquercetin was better
absorbed than quercetin by rats. Furthermore, isoquer-
cetin has been shown to play protective roles against
lipid peroxidation and oxidative stress [12]. Accumu-
lated evidence has suggested that diabetic patients are
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free radical-generating and radical-scavenging capacity.
The increased free radical production and reduced anti-
oxidant defense may partially mediate the initiation and
progression of diabetes-associated complications [13,14].
Here we reported our investigations on the effect of iso-
quercetin on diabetic KK-A
y mice.
Materials and methods
Preparation of isoquercetin from Tartary Buckwheat
The isoquercetin was prepared from tartary buckwheat
provided by the Chinese National Genebank (Beijing,
China) using the method of Chang and Muir [15].
Briefly, buckwheat was extracted with 50% methanol
aqueous solution at 40°C for 3 hours. After vacuum fil-
tration at 50°C, the supernatants were combined and
concentrated to one-third of the volume under a
reduced pressure using a rotary evaporator. The concen-
trate was dispersed in 500 ml of water (solid:liquid ratio
= 1:100). Then the dispersion was heated to 80°C and
the pH adjusted to 4, followed by the addition of narin-
gin enzyme. After further purification by a preparative
HPLC method, the isoquercetin purity was 96.7%, which
was detected by an analytical HPLC procedure.
Design of animal experiment
Experiments were carried out according to the method
of Yao et al. [16]. Forty male diabetic KK-A
y mice [17]
were obtained from the Department of Laboratory Ani-
mal Science Center (Beijing, China). The diabetic mice
were divided into four groups according to their weights
and blood glucose levels to make the average weights
and blood glucose levels similar among the groups:
group I, control diabetic animals (n = 10); group II, dia-
betic animals given 200 mg of isoquercetin/kg, n = 10);
group III, diabetic animals given 100 mg of isoquerce-
tin/kg, n = 10); group IV, diabetic animals given 50 mg
of isoquercetin/kg, n = 10). Body weights were measured
during the treatment. All mice were housed individually
in stainless steel wire-bottom cages in an air-condi-
tioned room kept at controlled ambient temperature (22
± 1°C), humidity (50 ± 10%), and a 12 h light/dark
cycle. The composition of the diets fed to the mice was
shown in Table 1. They were allowed free access to the
diet and water. The level of food intake was measured
weekly. The experiment was carried out according to
the European Community Guidelines for the Use of
Experimental Animals and approved by the Peking Uni-
versity Committee on Animal Care and Use.
Fasting blood glucose levels and oral glucose tolerance
test (OGTT)
Blood samples were taken from the tail vein weekly after
overnight fasting. Glucose was determined according to
the method of Yao et al. [16] using glucose analyzes
(ACCU-CHEK Active, Roche, Shanghai, China). On the
morning of OGTT, fasting animals were given glucose
orally (2 g/kg). Blood glucose levels were measured at 0
(before oral glucose), 30, 60, and 120 min after glucose
administration.
Plasma biomarker analyses
Blood was collected from abdominal artery into a
heparin-coated tube and centrifuged at 1000 g for 15
min at 4°C, the plasma was colleted and stored at -20°C
until analysis [18]. Plasma insulin (DSL-1600 Insulin
RIA kit, Diagnostic Systems Laboratories, USA) level
was measured based on a radio-immunometric assay. C-
peptide (ADL, San Diego, CA) and glucagon (RapidBio
Laboratory, Calabasas, CA) were determined using com-
mercial enzyme-linked immunosorbent assay kits.
Plasma total cholesterol, triglycerides, and blood urea
nitrogen (BUN) were measured using an autobiochem-
ical analyzer (Hitachi 7600, Japan) [19-21].
Immunohistochemical evaluation on pancreas
The pancreas was removed immediately after sacrifice
and rinsed in ice-cold saline. The tissue samples were
fixed in paraformalclehyde, dehydrated in a graded ser-
ies of ethanol, and embedded in paraffin wax before sec-
tioning. Sections were immersed in a solution of 3%
H2O2 for 10 min then preincubated with nonimmune
serum for 15 min and subsequently replaced with the
mouse anti-insulin antibody (1:200, SP-9000, ZYMED,
CA) for incubation at 4°C for 16 h. Biotinylated goat
anti-mouse immunoglobulin was used as a secondary
antibody. They were labeled with streptavidin peroxidase
followed by incubation with the secondary antibody at
37°C for 30 min. The localization of the antigen was
indicated by a brown color obtained with 3-amino-9-
Table 1 Composition of the Experimental Diet
Content KK-A
y
corn starch 28.21
soybean meal (%) 11.62
soybean powder (%) 4.13
wheat flour (%) 14.00
wheat bran (%) 7.42
fish powder (%) 0.84
CaCO3 (%) 1.33
CaPO4 (%) 1.54
mineral (%) 0.56
vitamin (%) 0.07
soybean (%) 0.28
sucrose (%) 10.00
lard (%) 10.00
Yolk powder (%) 10.00
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Page 2 of 6ethyl-carbazole (AEC) as a chromogenic substrate for
peroxidase activity. Slides were counterstained with
hematoxylin for microscopic observation. The specificity
of the immunohistochemical staining was checked by
omission of the primary antibody or by using an inap-
p r o p r i a t ea n t i b o d y( a n t i g a s t r i n ) .M o r et h a n1 0i s l e t si n
each mice group were randomly selected and transferred
to a pathology image analyzing system. Staining signals
of the islets selected on the captured image were con-
verted to gray density which can be automatically calcu-
lated as a staining intensity per unit area.
Statistical analysis
All values were expressed as mean ± SD. Data were ana-
lyzed using one-way analysis of variance (ANOVA). Dif-
ferences with p < 0.05 were considered to be significant.
Results and discussion
Food intake and body weight
KK-A
y mice have high fasting and nonfasting blood glu-
cose levels similar to human type 2 diabetes. The pre-
sent study found that isoquercetin had no effect on the
final body weight of KK-A
y mice during the 5-week per-
iod of treatment (Table 2).
Fasting blood glucose levels and oral glucose tolerance
Isoquercetin was hypoglycemic in KK-A
y mice (Figure
1). Oral administration of isoquercetin for 5 weeks
caused a dose dependent decerease in blood glucose
level compared with the control diabetic group (Figure
1). Isoquercetin appeared to improve the glucose toler-
ance in KK-A
y mice (Figure 2). The KK-A
y control mice
showed a sharply increased blood glucose concentration
at 30 min after glucose loading and maintained this
high level for over an additional 60 min. All isoquerce-
tin-treated KK-A
y mice showed decreases in blood glu-
cose levels at 60 and 120 min compared with the
control KK-A
y mice (Figure 2). Isoquercetin is a poten-
tial substrate for the lactase phloridzin hydrolase in the
brush border membrane [22-24]. It is assumed that the
hydrophilic monoglucoside might concentrate at the
brush border membrane and be deglycosylated by this
enzyme. The lipophilic aglycone is thought to be able to
penetrate the apical enterocyte membrane by passive
diffusion. Consequently, the higher concentration of
quercetin originating adjacent to the apical membrane
would result in a higher diffusion rate at this site and,
thus, in greater absorption of the isoquercetin.
Plasma biomarker levels
Isoquercetin (200 mg/kg) significantly lowered the levels
of plasma insulin and C-peptide (p < 0.01), which is a
byproduct of insulin production. Newly C-peptide levels
are measured instead of insulin levels because insulin
concentration in the portal vein ranges from two to ten
times higher than in the peripheral circulation. The liver
extracts about half the insulin reaching it in the plasma,
but this varies with the nutritional state. The pancreas
of patients with type 1 diabetes is unable to produce
insulin and therefore they will usually have a decreased
level of C-peptide, whereas C-peptide levels in type 2
patients are normal or higher than normal. Measuring
C-peptide in patients injecting insulin can help to deter-
mine how much of their own natural insulin these
patients are still producing.
In this study, the KK-A
y mice displayed hyperglucago-
nemia (p < 0.001) and isoquercetin lowered the plasma
glucagon level compared to the control diabetic mice
(Table 3). Glucagon is one of several hormones that
possess antagonistic action against insulin that can
exacerbate the metabolic consequences of insulin defi-
ciency. The suppression of endogenous glucose produc-
tion has been reported to be not just as a simple
response to insulin but rather as a complex interplay
between the action of glucagons and insulin [25]. Thus,
the improvement in hyperglycemia by isoquercetin
could be partly attributable to the amelioration of
hyperglucagonemia.
The most common lipid abnormalities in diabetes are
hypertriglyceridemia and hypercholesterolemia [26]. In
the present study, plasma lipids including cholesterol
and triglycerides in diabetic mice were elevated (Table
3). Isoquercetin (200 mg/kg) decreased the level of tri-
glyceride and total cholesterol may be due to the
increased insulin releasing capacity [27].
Diabetic hyperglycemia induces the elevation of
plasma urea nitrogen, which is considered to be a mar-
ker of renal dysfunction [28]. As shown in Table 3,
plasma urea in isoquercetin group (200 mg/kg) reduced
significantly plasma urea nitrogen by 12.8% (p < 0.05)
compared with the value of the diabetic control group,
indicating that isoquercetin may capable of ameliorating
Table 2 Effect of Isoquercetin on Body Weight and Food Intake (week) in Diabetic KK-A
y
Initial body wt (g) Final body wt (g) Food intake (g)
control diabetic mice 36.49 ± 1.72 37.51 ± 1.42 11.56 ± 0.97
diabetic mice given 200 mg of isoquercetin/kg 35.43 ± 1.35 36.86 ± 1.87 12.32 ± 1.19
diabetic mice given 100 mg of isoquercetin/kg 37.21 ± 1.79 37.75 ± 1.68 10.08 ± 0.95
diabetic mice given 50 mg of isoquercetin/kg 37.09 ± 1.40 37.93 ± 1.53 11.53 ± 1.62
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hypoglycemic control.
Immunohistochemical level on pancreas
Isoquercetin treatment group (200 mg/kg) increased the
area of insulin immunoreactive b-cells in the pancreatic
islets significantly compared with the diabetic group (Figure
3 and 4), suggesting that the rate of apoptotic in the islet b-
cells was slowed. Numerous documents have demonstrated
that oxidative stress usually promotes the production of
reactive nitrogen species and reactive oxygen species,
which can change in the mitochondrial membrane
Figure 1 Changes in blood glucose levels in different experimental groups. Each column represents the mean ± S.D. of 10 animals.
a P<
0.05,
bP < 0.01,
cP < 0.001, compared with the control.
Figure 2 Oral glucose tolerance test at the end of the 5-week treatment.
ap < 0.05,
bp < 0.01 compared with the control.
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apoptosis [29]. In view of a report by Silva [12] who
reported isoquercetin play protective roles against oxidative
stress, therefore isoquercetin may also protect the pancrea-
tic b-cells from type 2 diabetes mellitus related apoptosis.
Conclusions
Isoquercetin had a regulative role in blood glucose level
and lipids, and improved the function of pancreatic
islets. Isoquercetin may be useful in the treatment of
type 2 diabetes mellitus.
Table 3 Plasma Parameters in Diabetic KK-A
ya
C-peptide
(ng/mL)
glucagons
(pg/mL)
triglycerides
(mmol/L)
total cholesterol (mmol/L) BUN
b
(mmol/L)
control diabetic mice 0.84 ± 0.09 107.73 ± 4.65 1.03 ± 0.12 4.98 ± 0.63 11.79 ± 2.40
diabetic mice given 200 mg of isoquercetin/kg 0.65 ± 0.21 a 67.29 ± 6.37c 0.83 ± 0.14 b 3.79 ± 0.67 a 9.35 ± 0.49 a
diabetic mice given 100 mg of isoquercetin/kg 0.76 ± 0.13 72.81 ± 7.58 b 0.86 ± 0.09 a 4.30 ± 0.36 11.26 ± 0.81
diabetic mice given 50 mg of isoquercetin/kg 0.81 ± 0.26 103.52 ± 8.29 0.90 ± 0.11 a 4.74 ± 0.52 10.94 ± 1.38
a “a”, P < 0.05; “b”, P < 0.01; “c”, P < 0.001, compared with the diabetic control mice.
b BUN, blood urea nitrogen.
Figure 3 Immunohistochemical evaluation on pancreas (400 ×): (A) Diabetic KK-A
y mice showing the decrease of insulin
immunoreactivity, (B) Diabetic KK-A
y mice orally given isoquercetin (200 mg/kg) showing an improvement in insulin
immunoreactivity.
Figure 4 Comparative evaluation of the expression of insulin immunoreactivity in the pancreatic islets.* * p <0 . 0 1a n d* p <0 . 0 1
compared with the control diabetic mice.
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